Trial · NCT06187441
FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
NCT06187441, Phase 3, Recruiting, Stichting Hemato-Oncologie voor Volwassenen Nederland
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM). Trials, record NCT06187441. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06187441
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM)
- NCT number
- NCT06187441
- Status
- Recruiting
- Phases
- Phase 3
- Enrollment
- 599 participants, estimated
- Lead sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Conditions
- Multiple Myeloma
- Interventions
- Daratumumab Injection, Dexamethasone, Lenalidomide capsule
- First posted
- 2024-01-02
- Last updated
- 2024-08-19
Source ClinicalTrials.gov
Registered outcomes16
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Compare Event-Free Survival (EFS) | Approximately up to 57 (EFS) months after randomization of the first patient | To compare Event-Free Survival (EFS) from the time of randomization, between arm A continuous therapy with Dara-Rd until PD versus arm B discontinuation of therapy with Dara-Rd, resuming therapy at the first signs of biochemical progression until PD |
| Primary | Compare Progression Free Survival (PFS) | Approximately up to 69 (PFS) months after randomization of the first patient | To compare Progression Free Survival (PFS) from the time of randomization, between arm A continuous therapy with Dara-Rd until PD versus arm B discontinuation of therapy with Dara-Rd, resuming therapy at the first signs of biochemical progression until PD |
| Secondary | Compare adverse event burden | Approximately up to 69 months after randomization of the first patient | To compare adverse event (AE) burden between arms |
| Secondary | Compare patient-reported outcome measures (PROMs) | Approximately up to 69 months after randomization of the first patient | To compare PROMs between arms via validated questionnaires such as Impact of Cancer version 2 Cancer Worry scale |
| Secondary | Compare cost-effectiveness between arms | Approximately up to 69 months after randomization of the first patient | To compare cost-effectiveness between arms |
| Secondary | Determine the length of the treatment-free interval | Approximately up to 69 months after randomization of the first patient | To determine the length of the treatment-free interval (TFI) in arm B |
| Secondary | Determine time to (maximal) response response | Approximately up to 69 months after randomization of the first patient | To determine time to (maximal) response after restart of Dara-Rd in arm B. |
| Secondary | Compare time to next treatment | Approximately up to 69 months after randomization of the first patient | To compare time to next treatment (TTNT) between arms |
| Secondary | Compare time from randomization to progression on second-line therapy | Approximately up to 69 months after randomization of the first patient | To compare time from randomization to progression on second-line therapy (PFS2) between arms. |
| Secondary | Compare Overall Survival | Approximately up to 69 months after randomization of the last patient | To compare Overall Survival (OS) between arms. |
1 to 10 of 16Source ClinicalTrials.gov
See all 16 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06187441
GET https://conductscience.org/api/trials/v1/NCT06187441/registered